

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

D13

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ :	A1	(11) International Publication Number: WO 89/ 04669
A61K 31/415, 31/435, 31/445 A61K 31/46, 31/55		(43) International Publication Date: 1 June 1989 (01.06.89)
(21) International Application Number: PCT/GB88/00994		(74) Agents: JONES, Pauline et al.; Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).
(22) International Filing Date: 14 November 1988 (14.11.88)		
(31) Priority Application Numbers: 8726716 8726717		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.
(32) Priority Dates: 14 November 1987 (14.11.87) 14 November 1987 (14.11.87)		
(33) Priority Country: GB		
(71) Applicant (<i>for all designated States except US</i>): BEECHAM GROUP PLC [GB/GB]; Beecham House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		Published <i>With international search report.</i>
(72) Inventor; and		
(75) Inventor/Applicant (<i>for US only</i>) : WILLIAMS, Andrew, James [GB/GB]; Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).		

(54) Title: 5-HT₃ RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICITION

(57) Abstract

A method of treatment of cough and/or bronchoconstriction in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a 5-HT₃ receptor antagonist.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

- 1 -

5-HT₃ receptor antagonists for treatment of cough and bronchoconstriction.

5

This invention relates to a method of treatment of cough and/or bronchoconstriction in mammals, including humans, and to the use of compounds in the preparation of a medicament for the treatment of cough and/or 10 bronchoconstriction.

15 GB 2125398A, EP-A-200444, EP-A-247266, EP-A-235878, EP-A-67770, EP-A-158265, EP-A-158532 and EP-A-254584 disclose classes of compounds which are 5-HT₃ receptor antagonists, useful in the treatment of inter alia migraine, cluster headache and trigeminal neuralgia. GB 2153821A describes a further class of SHT₃ receptor antagonists.

20 It has now been discovered that SHT₃ receptor antagonists, such as certain of the above classes of compounds, are of potential use in the treatment of cough and/or bronchoconstriction, such as that arising as a result of asthma.

25


Cough is useful when it effectively expels secretions i.e. when it is a productive cough. Dry or unproductive cough has no useful effect. Unproductive cough may arise from effects such as cancer (primary or 30 secondary) affecting sensory nerves in the larynx or larger bronchi, from asthma - especially childhood asthma - and in the early or later stages of coryza. Unproductive cough may also occur due to infiltration of the cough centre in the brain by tumour. Cough may 35 also occur without known cause.

Treatment of cough by drugs is unsatisfactory.

- 2 -

Peripheral stimulation of sensory nerves in the larynx (which can cause cough) can be blocked by local anaesthetics such as lignocaine, but the only effective 5 form of therapy for dry and painful cough used clinically is provided by the opiates (morphine, codiene, and methadone etc.).

Accordingly, the present invention provides a method of 10 treatment of cough and/or bronchoconstriction in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a 5-HT₃ receptor antagonist, such as a compound of formula (I) or (II) or a 15 pharmaceutically acceptable salt thereof:




(I)

wherein


20 X is a group of formula (a), (b), (c), (d) or (e):

25




30

35




- 3 -

5




(c)

10



(d)

15



(e)

20

wherein

R_a to R_d are selected from hydrogen, halogen or hydroxy;

R₁ is hydrogen and R₂ is hydrogen or C₁₋₄ alkyl; or
25 R₁ and R₂ together are a bond;

R₃ to R₇ are independently hydrogen or C₁₋₆ alkyl; and
R₄ together with R₂ may be C₂₋₇ polymethylene when R₁
is hydrogen;

either R₈ is C₁₋₆ alkoxy;

30 R₉ is hydrogen;

R₁₀ is amino or C₁₋₇ alkanoylamino; and

R₁₁ is halo or C₁₋₆ alkylthio; or

R₈ is hydrogen;

R₉ is halo, C₁₋₆ alkoxy or C₁₋₆ alkyl;

35 R₁₀ is hydrogen or C₁₋₆ alkoxy; and

R₁₁ is halo, C₁₋₆ alkoxy or C₁₋₆ alkyl;

L is CH or N;

- 4 -


Y is NH or O, with the proviso that Y is NH when X is

(e) and R₈ is C₁₋₆ alkoxy;

Z is a group of formula (f), (g) or (h):

5


10



15



20




wherein

n is 2 or 3;

p and q are independently 1 to 3; and

25 R₁₂ or R₁₃ is methyl or ethyl;and with the proviso that, when Ar is of formula (b)
and Y is -NH-, Z is a group of formula (d) or (e);

30



35 wherein

R₁₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₆ alkenyl, phenyl or phenyl-C₁₋₃ alkyl; and

- 5 -

one of the groups represented by R_{13} , R_{14} and R_{15} is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{2-6} alkenyl or phenyl- C_{1-3} alkyl and each of the other groups, which may be the same or different, is hydrogen or C_{1-6} alkyl.

5

In formula (I):

10 Examples of moieties in alkyl or alkyl containing groups in R_1 to R_{11} include methyl, ethyl, n - and iso-propyl, n -, iso-, sec- and tert-butyl, preferably methyl.

15 Suitable examples of R_2 and R_4 when joined include C_2 , C_3 , C_4 , C_5 or C_6 polymethylene, preferably C_2 , C_3 , C_4 or C_5 polymethylene.

20 R_a to R_d are preferably selected from hydrogen, fluoro, chloro and hydroxy, most preferably hydrogen. R_b may be 5-, 6- or 7-chloro or fluoro.

When X is of sub-formula (a), R_1 and R_3 are preferably both hydrogen and one or both of R_2 and R_4 (most 25 preferably both) are alkyl groups, such as methyl, or are joined to form C_{2-7} polymethylene; or when one of R_2 and R_4 is hydrogen, the other is preferably ethyl or n - or iso- propyl.

30 When X is of sub-formula (b), R_5 is preferably hydrogen or a methyl or ethyl group.

When X is of sub-formula (c), one of $CO-Y-Z$ and R_6 is attached at the 1-position and the other is attached at 35 the 3-position as depicted in sub-formula (c), and R_6 is preferably methyl or ethyl.

- 6 -

When X is of sub-formula (d), R₇ is preferably methyl.

When X is of sub-formula (e), and R₈ is C₁₋₆ alkoxy, R₈ 5 is preferably methoxy, R₁₀ is preferably amino and R₁₁ is preferably chloro or bromo, most preferably chloro.

When X is of sub-formula (e), and R₈ is hydrogen, R₉ and R₁₁ are preferably chloro or methyl and R₁₀ is 10 preferably hydrogen.

X is preferably a group of formula (b) and L is preferably N.

15 Y is preferably NH.

When Z is a group of sub-formula (f), n is 2 or 3, preferably 3 when X is of sub-formula (b) wherein L is N.

20

When Z is a group of sub-formula (g) or (h), p and q are preferably 1 or 2.

In formula (II):

25

It will be understood that when R₁₂ represents a C₃₋₆ alkenyl group, the double bond may not be adjacent to the nitrogen atom.

30 The alkyl groups represented by R₁₂, R₁₃, R₁₄ and R₁₅ may be for example, methyl, ethyl, propyl, prop-2-yl, butyl, but-2-yl, methylprop-2-yl, pent-3-yl or hexyl.

An alkenyl group may be, for example, a propenyl group.

35

A phenyl-C₁₋₃ alkyl group may be for example, a benzyl, phenethyl or 3-phenylpropyl group. A cycloalkyl group

- 7 -

may be, for example, a cyclopentyl, cyclohexyl or cycloheptyl group.

- 5 The pharmaceutically acceptable salts of the compounds of the formulae (I) and (II) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as
10 acetic, tartaric, lactic, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, α -keto glutaric, α -glycerophosphoric, and glucose-1-phosphoric acids.

The pharmaceutically acceptable salts of the compounds of the formulae (I) and (II) are usually acid addition salts with acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.

- 20 Preferably the acid addition salt is the hydrochloride salt.

Pharmaceutically acceptable salts also include quaternary derivatives, examples of which include the
25 compounds quaternised by compounds such as R_x-T wherein R_x is C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or C₅₋₇ cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R_x include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
30 Suitable examples of T include halide such as chloride, bromide and iodide.

Pharmaceutically acceptable salts also include internal salts such as pharmaceutically acceptable N-oxides.

35

The compounds of the formulae (I) and (II), and their pharmaceutically acceptable salts may also form

- 8 -

pharmaceutically acceptable solvates, such as hydrates which are included whereverver a compound of formula (I) or (II), or a salt thereof is herein referred to.

5

It will of course be realised that some of the compounds of the formulae (I) and (II) have chiral or prochiral centres, and thus are capable of existing in a number of stereoisomeric forms, including 10 enantiomers. The invention extends to each of these stereoisomeric forms (including enantiomers), and to mixtures thereof (including racemates). The different stereoisomeric forms may be separated one from the other by the usual methods.

15

Compounds of the formulae (I) and (II) and their salts may be prepared in accordance with the methods described in the aforementioned Patent Publications. Examples of interest include the compounds within 20 formulae (I) and (II) which are specific examples in the aforementioned patent publications. Particular examples include the following compounds:

- i) The compound of Example 5 of EP-A-247266.
- 25 ii) The compound of Example 6 of EP-A-200444 (BRL 43694A).
- iii) The compound of Example A-2 of GB 2125398A (ICS 30 205-930).
- iv) The compound of Example 1 of EP-A-67770 (MDL 72222).
- 35 v) The compound of Example 1a of GB 2153821A (GR 38032F).

- 9 -

The administration of the 5-HT₃ receptor antagonist may be by way of oral or parenteral administration; or by inhalation.

5

An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the 10 mammal. However, a unit dose for a 70kg adult will normally contain 0.1 to 100mg for example 0.2 to 50mg, of the compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof. Unit doses may be administered once or more than once a day, for 15 example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0002 to 5 mg/kg/day, more usually 0.0004 to 2.5 mg/kg/day. In the case of the preferred compounds of the invention, the dose range is 0.0002 to 0.3 20 mg/kg/day.

No adverse toxicological effects are indicated at the aforementioned dosage ranges.

25 It is preferred that the 5-HT₃ receptor antagonist is administered in the form of a unit dose pharmaceutical composition in which is combined with a pharmaceutically acceptable carrier.

30 Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusible 35 solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.

- 10 -

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, 5 fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.

10

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch 15 glycollate. Suitable lubricants include, for example, magnesium stearate.

Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid 20 preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may 25 contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan 30 monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl 35 p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

- 11 -

Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product 5 for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or 10 colouring agents.

The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the 15 active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

For parenteral administration, fluid unit dose forms 20 are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a 25 vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can 30 be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended 35 in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a

- 12 -

surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

5

Compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns. Where appropriate, small amounts of other anti-asthmatics and bronchodilators, for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

20

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.

25 The present invention also provides the use of a 5-HT₃ receptor antagonist, such as compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of cough and/or bronchoconstriction in mammals, including humans. Such treatment may be carried out in the manner as hereinbefore described.

The present invention further provides a pharmaceutical composition for use in the treatment of cough and/or 35 bronchoconstriction which comprises an effective amount of a 5-HT₃ receptor antagonist, such as compound of formula (I) or (II), or a pharmaceutically acceptable

- 13 -

salt thereof, and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner as hereinbefore described.

5

The following clinical tests illustrate the invention.

Compound E6 is the Compound of Example 6 of EP-A-200444, N-(endo-9-methyl-9-azabicyclo-
10 [3.3.1]non-3-yl)-1-methyl-indazole-3-carboxamide monohydrochloride.

Clinical Tests

15 1. Experimental cough in man can be induced by inhalation of capsaicin (the active ingredient of pepper) and coughing occurs in a dose related manner. Administration of compound E6 intravenously at doses up to 60 µg/kg is found to block capsaicin induced cough.

20

2. Bronchoconstriction in man can be induced by inhalation of capsaicin (the active ingredient of pepper) or by inhalation of sulphur dioxide. Administration of compound E6 intravenously at doses of
25 up to 60 µg/kg is found to block capsaicin or sulphur dioxide induced bronchoconstriction.

- 14 -

Claims

1. A method of treatment of cough and/or
 5 bronchoconstriction in mammals, including humans, which
 method comprises the administration to the mammal in
 need of such treatment, an effective amount of a 5-HT₃
 receptor antagonist.
- 10 2. A method according to claim 1 wherein the 5-HT₃
 receptor antagonist is a compound of formula (I) or
 (II) or a pharmaceutically acceptable salt thereof:

X-CO-Y-Z


(I)

15

wherein

X is a group of formula (a), (b), (c), (d) or (e):


20



(a)


25

30



(b)


35



(c)


- 15 -

5



(d)

10






(e)

15 wherein

- R_a to R_d are selected from hydrogen, halogen or hydroxy;
- R₁ is hydrogen and R₂ is hydrogen or C₁₋₄ alkyl; or R₁ and R₂ together are a bond;
- 20 R₃ to R₇ are independently hydrogen or C₁₋₆ alkyl; and R₄ together with R₂ may be C₂₋₇ polymethylene when R₁ is hydrogen;
- either R₈ is C₁₋₆ alkoxy;
- R₉ is hydrogen;
- 25 R₁₀ is amino or C₁₋₇ alkanoylamino; and R₁₁ is halo or C₁₋₆ alkylthio; or R₈ is hydrogen;
- R₉ is halo, C₁₋₆ alkoxy or C₁₋₆ alkyl;
- R₁₀ is hydrogen or C₁₋₆ alkoxy; and
- 30 R₁₁ is halo, C₁₋₆ alkoxy or C₁₋₆ alkyl;
- L is CH or N;
- Y is NH or O, with the proviso that Y is NH when X is (e) and R₈ is C₁₋₆ alkoxy;
- Z is a group of formula (f), (g) or (h):

- 16 -




wherein

n is 2 or 3,

20 p and q are independently 1 to 3; and

R12 or R13 is methyl or ethyl;

and with the proviso that, when Ar is of formula (b)
and Y is -NH-, Z is a group of formula (d) or (e);



30

wherein

R12 is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₆ alkenyl, phenyl or phenyl-C₁₋₃ alkyl; and

one of the groups represented by R13, R14 and R15 is
35 hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl or phenyl-C₁₋₃ alkyl and each of the

- 17 -

other groups, which may be the same or different, is hydrogen or C₁₋₆ alkyl.

5 3. A method according to claim 2 wherein the compound of formula (I) is the compound of Example 5 of EP-A-247266.

4. A method according to claim 2 wherein the compound of formula (I) is BRL 43694A.

5. A method according to claim 2 wherein the compound of formula (I) is ICS 205-930.

15 6. A method according to claim 2 wherein the compound of formula (I) is MDL 72222.

7. A method according to claim 2 wherein the compound of formula (II) is GR 38032F.

20 8. Use of a 5-HT₃ receptor antagonist as defined in any one of claims 1 to 7 in the preparation of a medicament for use in the treatment of cough and/or bronchoconstriction in mammals, including humans.

25 9. A pharmaceutical composition for use in the treatment of cough and/or bronchoconstriction, which comprises an effective amount of a 5-HT₃ receptor antagonist, and a pharmaceutically acceptable carrier.

30

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 88/00994

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁴

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁴ : A 61 K 31/415; 31/435; 31/445; 31/46; 31/55

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System	Classification Symbols
IPC	A 61 K 31/00

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁵

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁶

Category ⁷	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	J. Physiol. (London), vol. 365, 1985, (GB) D.J. Armstrong et al.: "MDL 72222 (a 5-HT antagonist) antagonizes the pulmonary depressor and respiratory chemoreflexes evoked by phenylbiguanide in anaesthetized rabbits" page 104P, see page 104P	8,9
A	Br.J. Pharmacol., vol. 87, no. 2, February 1986 The Macmillan Press Ltd; H.E. Connor et al. "5-carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats" pages 417-426, see the abstract	8,9
A	Chest, vol. 92, no. 5, November 1987 M. Cazzola et al.: "Ketanserin, a new blocking agent of serotonin S ₂ -receptors	8,9

* Special categories of cited documents: ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

10th February 1989

Date of Mailing of this International Search Report

09 MAR 1989

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

P.C.G. VAN DER PUTTEN

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A | Respiratory functional effects in chronic
obstruction of the airways"
pages 863-866,
see the abstract

A | Allgemeine und Spezielle Pharmakologie und
Toxikologie, 3rd Edition, Bibliographisches Institut, Mannheim (DE)
1980, page 151
see page 151

8,9

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE:

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers 1-7, because they relate to subject matter not required to be searched by this Authority, namely:

See PCT-rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy as well as diagnostic methods.

2. Claim numbers, because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING:

This International Searching Authority found multiple inventions in this International application as follows:

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

